FDA To Assess Gaps Between Drug Review And Product Label Content
This article was originally published in The Tan Sheet
Executive Summary
FDA will evaluate drug review documents and approved product labeling for gaps in information as part of a quality assurance effort for drug reviews in the Center for Drug Evaluation & Research.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning